Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-02-20
DOI
10.1007/s00228-021-03106-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis
- (2019) Emma J.M. Grigor et al. TRANSFUSION MEDICINE REVIEWS
- Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy
- (2019) Huiwen Jiang et al. ANNALS OF HEMATOLOGY
- Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters
- (2019) Yong Gu Lee et al. Nature Communications
- Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia
- (2019) Jie Li et al. ADVANCES IN THERAPY
- Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
- (2019) Shengnan Yu et al. Molecular Cancer
- Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts
- (2018) Ping-Pin Zheng et al. DRUG DISCOVERY TODAY
- Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
- (2018) David Porter et al. Journal of Hematology & Oncology
- CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
- (2018) Theodoros Giavridis et al. NATURE MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy
- (2018) Noelle Frey et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
- (2018) Joe-Elie Salem et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- The value of patient reporting to the pharmacovigilance system: a systematic review
- (2016) Pedro Inácio et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Toxicity and management in CAR T-cell therapy
- (2016) Challice L Bonifant et al. Molecular Therapy-Oncolytics
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- WHO Strategy for Collecting Safety Data in Public Health Programmes: Complementing Spontaneous Reporting Systems
- (2013) Shanthi N. Pal et al. DRUG SAFETY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started